The approach, developed by investigators at Vanderbilt-Ingram Cancer Center, shows that erlotinib ??? a targeted therapy that acts on a growth factor receptor mutated in some lung, brain and other cancers ??? doesn???t simply kill tumor cells as was previously assumed.